Compare VPG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | ADCT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.2M | 496.7M |
| IPO Year | N/A | 2020 |
| Metric | VPG | ADCT |
|---|---|---|
| Price | $38.12 | $4.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 121.6K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $299,283,000.00 | $75,209,000.00 |
| Revenue This Year | $0.48 | $10.36 |
| Revenue Next Year | $4.94 | $3.87 |
| P/E Ratio | $63.45 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $18.57 | $1.05 |
| 52 Week High | $39.86 | $4.80 |
| Indicator | VPG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.65 | 54.80 |
| Support Level | $36.36 | $3.15 |
| Resistance Level | $39.86 | $4.32 |
| Average True Range (ATR) | 1.57 | 0.38 |
| MACD | 0.40 | 0.03 |
| Stochastic Oscillator | 78.73 | 77.08 |
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).